Dateline City:
KENILWORTH, N.J.
Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation
EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced efficacy and safety data in previously untreated adults
with HIV-1 infection for the companys investigational once-daily
formulation of ISENTRESS (raltegravir), known as raltegravir
600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal
trial called ONCEMRK.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Carmen de Gourville, 267-305-4195orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more